Abstract
This formal correction addresses a data presentation error in the original article published in Nature Communications. Specifically, a western blot image for PD-L1 in Figure 6k was inadvertently duplicated from Figure 3j. The corrected Figure 6k provided here confirms the original scientific conclusions regarding the role of TMUB1 and the E3 ligase HUWE1 in regulating PD-L1 stability.
Introduction
Cancer cells frequently exploit the PD-L1 (Programmed Death-Ligand 1) checkpoint to evade immune surveillance. The stability and cell-surface presence of PD-L1 are tightly regulated by post-translational modifications, including polyubiquitination and glycosylation. This research identifies TMUB1 (Transmembrane and Ubiquitin-like domain-containing protein 1) as a key scaffold protein that modulates these processes, thereby controlling anti-tumor immunity.
Mapping the TMUB1-PD-L1 Interaction
To understand how TMUB1 regulates PD-L1, researchers mapped the physical interaction between the two proteins. Using various deletion mutants, they identified that the UBL (Ubiquitin-like) domain of TMUB1, specifically residues 88-102, is critical for binding to PD-L1.
Mechanism of PD-L1 Degradation
The study reveals that TMUB1 facilitates the recruitment of HUWE1, an E3 ubiquitin ligase, to PD-L1. This recruitment leads to the polyubiquitination and subsequent proteasomal degradation of PD-L1. A synthetic peptide, PTPR, was designed to mimic the binding interface and modulate this pathway.
The corrected data in Figure 6k demonstrates that PTPR treatment enhances the interaction between HUWE1 and PD-L1, promoting PD-L1 degradation. This mechanism is summarized in the model shown in Figure 6l.
Functional Impact on Anti-Tumor Immunity
The functional consequences of targeting the TMUB1-PD-L1 axis were evaluated using co-culture assays with MDA-MB-231 breast cancer cells and T cells. PTPR treatment significantly reduced tumor cell survival (Fig. 6m) and boosted the expression of key pro-inflammatory cytokines, IFN-γ and TNF-α (Fig. 6n, o). These results suggest that disrupting the TMUB1-mediated stabilization of PD-L1 can effectively "unmask" tumor cells to the immune system.
Conclusion
The correction of Figure 6k ensures the accuracy of the biochemical evidence supporting the TMUB1-HUWE1-PD-L1 regulatory axis. These findings highlight TMUB1 as a promising therapeutic target for enhancing the efficacy of cancer immunotherapies by promoting the natural degradation of immune checkpoints.
Summary updated